Document Classification

Section Type: RESULTS

Text: In the per-protocol analysis of first episodes of infections due to vaccine-type strains, community-acquired pneumonia occurred in 49 persons in the PCV13 group and 90 persons in the placebo group (vaccine efficacy, 45. 6 % ; 95. 2 % confidence interval [CI], 21. 8 to 62. 5), nonbacteremic and noninvasive community-acquired pneumonia occurred in 33 persons in the PCV13 group and 60 persons in the placebo group (vaccine efficacy, 45. 0 % ; 95. 2 % CI, 14. 2 to 65. 3), and invasive pneumococcal disease occurred in 7 persons in the PCV13 group and 28 persons in the placebo group (vaccine efficacy, 75. 0 % ; 95 % CI, 41. 4 to 90. 8).